An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic
effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological
support, to explore the potential effects on alcohol use and related symptoms in patients
with Alcohol Use Disorder.